Retaglutide and tirzepatide are innovative GLP-1 receptor agonists gaining recognition as effective treatment options for type 2 diabetes. These medications stimulate insulin secretion from the pancreas, suppress glucagon release, and prolong gastric emptying, leading to improved glycemic control. Retaglutide is administered subcutaneously, while t